Re: In Vivo and in Vitro Effects of Xenogeneic Immune Ribonucleic Acid in Patients with Advanced Renal Cell Carcinoma: A Phase I Study, by Jerome P. Richie, Bosco S. Wang, Glenn D. Steele, Jr., Richard E. Wilson and John A. Mannick, J. Urol., 126: 24–28, 1981

1982 ◽  
Vol 127 (4) ◽  
pp. 783-783
Author(s):  
Neil H. Bander
1981 ◽  
Vol 126 (1) ◽  
pp. 24-27 ◽  
Author(s):  
Jerome P. Richie ◽  
Bosco S. Wang ◽  
Glenn D. Steele ◽  
Richard E. Wilson ◽  
John A. Mannick

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 16020-16020 ◽  
Author(s):  
P. Fischer ◽  
P. Patel ◽  
M. A. Carducci ◽  
D. F. McDermott ◽  
G. R. Hudes ◽  
...  

2015 ◽  
Vol 33 (5) ◽  
pp. 1040-1047 ◽  
Author(s):  
Matthew Zibelman ◽  
Yu-Ning Wong ◽  
Karthik Devarajan ◽  
Lois Malizzia ◽  
Alycia Corrigan ◽  
...  

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Junjie Cen ◽  
Yanping Liang ◽  
Yong Huang ◽  
Yihui Pan ◽  
Guannan Shu ◽  
...  

Abstract Background There is increasing evidence that circular RNAs (circRNAs) have significant regulatory roles in cancer development and progression; however, the expression patterns and biological functions of circRNAs in renal cell carcinoma (RCC) remain largely elusive. Method Bioinformatics methods were applied to screen for circRNAs differentially expressed in RCC. Analysis of online circRNAs microarray datasets and our own patient cohort indicated that circSDHC (hsa_circ_0015004) had a potential oncogenic role in RCC. Subsequently, circSDHC expression was measured in RCC tissues and cell lines by qPCR assay, and the prognostic value of circSDHC evaluated. Further, a series of functional in vitro and in vivo experiments were conducted to assess the effects of circSDHC on RCC proliferation and metastasis. RNA pull-down assay, luciferase reporter and fluorescent in situ hybridization assays were used to confirm the interactions between circSDHC, miR-127-3p and its target genes. Results Clinically, high circSDHC expression was correlated with advanced TNM stage and poor survival in patients with RCC. Further, circSDHC promoted tumor cell proliferation and invasion, both in vivo and in vitro. Analysis of the mechanism underlying the effects of circSDHC in RCC demonstrated that it binds competitively to miR-127-3p and prevents its suppression of a downstream gene, CDKN3, and the E2F1 pathway, thereby leading to RCC malignant progression. Furthermore, knockdown of circSDHC caused decreased CDKN3 expression and E2F1 pathway inhibition, which could be rescued by treatment with an miR-127-3p inhibitor. Conclusion Our data indicates, for the first time, an essential role for the circSDHC/miR-127-3p/CDKN3/E2F1 axis in RCC progression. Thus, circSDHC has potential to be a new therapeutic target in patients with RCC.


2014 ◽  
Vol 37 (3) ◽  
pp. 180-186 ◽  
Author(s):  
Paul Monk ◽  
Elaine Lam ◽  
Amir Mortazavi ◽  
Kari Kendra ◽  
Gregory B. Lesinski ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document